View the characteristics of the SJLIFE cohort relative to the CCSS cohort. The table was last updated October 31, 2022.
Study Population
Characteristics of SJLIFE Cohort Relative to the CCSS Cohort |
|||
|---|---|---|---|
Characteristics |
SJLIFE Cohort (n=9366) Dx 1962-2012 |
CCSS Cohort (n=25,665) Dx 1970-99 |
|
Sex |
Female |
45.3% |
46.5% |
Male |
54.7% |
53.5% |
|
Race Ethnicity |
White not Hispanic |
76.8% |
79.4% |
Black not Hispanic |
16.9% |
6.2% |
|
American Indian/Alaska Native |
0.1% |
<1.0% |
|
Asian Pacific Islander |
0.5% |
0.5% |
|
Hispanic |
4.0% |
7.8% |
|
Other |
1.5% |
3.3% |
|
Unknown |
0.2% |
1.1% |
|
Primary Diagnosis |
Leukemia |
32.1% |
30.7% |
Lymphoma |
15.3% |
20.3% |
|
CNS tumor |
18.0% |
17.5% |
|
Embryonal tumors |
17.3% |
16.5% |
|
Bone and Soft Tissue Sarcoma |
11.9% |
15.0% |
|
Carcinoma |
0.8% |
0.0% |
|
Other |
4.6% |
0.0% |
|
Age at Diagnosis (yrs) |
0-4 |
42.1% |
39.7% |
5-9 |
22.7% |
22.5% |
|
10-19 |
34.2% |
36.1% |
|
20+ |
1.0% |
1.7% |
|
Years of Diagnosis |
1958-1969 |
2.7% |
0.0% |
1970-1979 |
12.1% |
25.8% |
|
1980-1989 |
20.7% |
39.2% |
|
1990-1999 |
24.2% |
35.0% |
|
2000+ |
40.3% |
0.0% |
|
Treatment Modalities |
Chemo + RT |
44.2% |
42.2% |
Chemo |
37.4% |
31.8% |
|
RT |
7.8% |
8.1% |
|
No Chemo/No RT |
10.6% |
8.8% |
|
Geographic distribution of SJLIFE participants
The SJLIFE cohort is geographically diverse with the largest proportion of participants from the mid-South region of the United States.
Recruitment status of SJLIFE
As of April 30, 2020, for survivors where attempts to contact have been initiated, 80.4% (6006/7467) have been successfully enrolled and 87.8% have enrolled or have confirmed their interest in participating. Of all eligible survivors who are alive, 73.5% (6006/8173) have thus far been enrolled and 80.2% have enrolled or confirmed their interest in participating.
Cohort Recruitment Summary
Survivor participants who have completed their baseline clinical assessment are invited to return for subsequent systematic evaluations at a minimum of every 5 years. As of April 30, 2020: 53% (2776/5229) of survivors who had completed a baseline clinical assessment have returned for one or more subsequent follow-up assessments.
Distribution of Pediatric Cancers
SJLIFE includes all pediatric hematological and solid malignancies.
Monthly New Survivor and Control Enrollments
